- Home
- CNEY vs SBFM Comparison
CNEY vs SBFM Comparison
Compare CNEY & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNEY | SBFM |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | China | United States |
| Employees | N/A | 50 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 4.7M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNEY | SBFM |
|---|---|---|
| Price | $0.58 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 4.2M | 59.4K |
| Earning Date | 02-13-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $40.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.25 |
| 52 Week High | $2.95 | $3.05 |
Technical Indicators
Market Signals| Indicator | CNEY | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 39.41 |
| Support Level | $0.58 | $1.61 |
| Resistance Level | $1.05 | $1.85 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 25.72 | 5.10 |
Price Performance
Historical ComparisonAbout CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.